Population-Based Assessment of Determining Treatments for Prostate Cancer | Oncology | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
Invited Commentary
April 2015

Population-Based Assessment of Determining Treatments for Prostate Cancer

Author Affiliations
  • 1Department of Urology, Medical University of South Carolina, Charleston
  • 2Departments of Urology and Medicine, Tulane University School of Medicine, New Orleans, Louisiana
  • 3The Hollings National Cancer Institute Designated Cancer Center, Medical University of South Carolina, Charleston
JAMA Oncol. 2015;1(1):67-68. doi:10.1001/jamaoncol.2014.183

Given the variable nature of prostate cancer and the multiple treatment options suggested by the National Comprehensive Cancer Network guidelines for low-, intermediate-, and high-risk prostate cancer,1 discerning what factors influence treatment choice is essential for understanding how to optimize the appropriate use of treatments and cancer outcomes. In the early 1990s, the pendulum had swung following the introduction of widespread prostate-specific antigen (PSA) screening and the annual number of radical prostatectomy procedures doubled, while “watchful waiting” became an approach for caring for older patients and men with comorbid illnesses. A comprehensive update on patterns of care for older men (>65 years) in the mid 2000s, where attitudes regarding expectant management for prostate cancer, is welcome and needed.2

×